Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver disease ranging from simple steatosis (hepatic triglyceride content [HTGC] > 5%), through steatohepatitis (fat plus inflammation and hepatocellular ballooning degeneration; NASH), to fibrosis and ultimately cirrhosis, in the absence of excessive alcohol consumption (a threshold of < 20 g/d for women and < 30 g/d for men is typically adopted). 1 Nonalcoholic fatty liver disease is strongly associated with features of the metabolic syndrome including abdominal obesity, insulin resistance or type 2 diabetes mellitus (T2DM) and atherogenic dyslipidaemia. 2, 3 Over the past few decades, lifestyles have become increasingly sedentary and dietary patterns have changed, leading to an increased prevalence of obesity and insulin resistance. 3 Against this background, NAFLD has rapidly become the most common cause of abnormal liver biochemistry in many countries and is predicted to be the most common indication for liver transplantation within a decade. [4] [5] [6] The prevalence of NAFLD and its natural history are reviewed elsewhere in this issue. 7 A substantial proportion of the population are at risk of progressive NAFLD due to the presence of obesity and insulin resistance. However, it is apparent that only a minority progress to more advanced disease characterized by NASH, advanced fibrosis, and hepatocellular carcinoma (HCC). 3 Indeed, studies in cohorts of patients that have undergone serial liver biopsies indicate that approximately 40% of NAFLD cases will develop progressive liver fibrosis while the remaining 60% exhibit stable disease or some degree of regression during long-term follow-up. 8, 9 Rates of fibrosis progression are also nonuniform, with some individuals progressing more rapidly than others. 8, 9 It should also be noted that liver-related mortality occurs in < 5% of NAFLD patients and is the third most common cause of death after cardiovascular disease and extrahepatic malignancy. 10 The reasons for these variations remain incompletely understood, but NAFLD is best considered a complex disease Keywords ► nonalcoholic fatty liver disease ► TM6SF2 ► PNPLA3 ► gene ► steatohepatitis ► fibrosis Abstract Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum that spans simple steatosis, through nonalcoholic steatohepatitis (NASH) to fibrosis and ultimately cirrhosis. Nonalcoholic fatty liver disease is characterized by substantial interpatient variation in rate of progression and disease outcome: Although up to 25% of the general population are at risk of progressive disease, only a minority experience associated liverrelated morbidity. Nonalcoholic fatty liver disease is considered a complex disease trait that occurs when environmental exposures act upon a susceptible polygenic background composed of multiple independent modifiers. Recent advances include the identification of PNPLA3 as a modifier of disease outcome across the full spectrum of NAFLD from steatosis to advanced fibrosis and hepatocellular carcinoma; and the discovery of TM6SF2 as a potential "master regulator" of metabolic syndrome outcome, determining not only risk of advanced liver disease, but also cardiovascular disease outcomes. In this article, the authors will review the field, discussing in detail the current status of research into these important genetic modifiers of NAFLD progression. trait where subtle interpatient variations including host genetic factors and environment interact to produce disease phenotype and determine disease progression. [11] [12] [13] Although the presence of NAFLD is principally determined by environmental factors, it is clear that genetic factors contribute and crucially determine how individuals respond to the challenge of calorific excess and consequent metabolic stressors. Although much work remains to be done, substantial progress in our understanding of genetic modifiers has been made. Here we will summarize the latest developments since we last reviewed the field, in particular focusing on the PNPLA3 and TM6SF2 genes. 13, 14 Evidence Indicative of a Genetic Component to NAFLD Susceptibility to high-prevalence diseases such as obesity, T2DM, cardiovascular disease, and NAFLD comprises a heritable component variously accounting for up to 30 to 50% of relative risk. 15 These complex traits result from environmental exposures acting on a susceptible polygenic background made up of multiple independent modifiers. 15, 16 Three strands of evidence suggest that there is a significant heritable component to NAFLD: familial aggregation, [17] [18] [19] twin studies, 20 and interethnic differences in susceptibility. [21] [22] [23] [24] [25] Although socioeconomic factors can confound analysis of interethnic differences, variations in population prevalence of genetic variants such as the PNPLA3 rs738409 polymorphism do seem to contribute to this variability. 26 
Identifying Genetic Modifiers of NAFLD
The allelic frequency of susceptibility loci in common diseases remains a contentious subject. [27] [28] [29] Most studies are founded on the pre-eminent "common disease/common variant" (CD/CV) hypothesis. 16, 28 Broadly, common diseases are of late onset, and so have little impact on reproductive fitness. Therefore, causative mutations are not subject to negative selection pressures, and disease susceptibility is due to the combined effects of multiple relatively common causative polymorphisms (minor allele frequency 1-5%) that are carried by affected individuals. 28 Discussion of the relative merits of this and the competing "multiple rare-variant" hypothesis is outside the scope of this review, but are discussed elsewhere. Although one cannot accurately predict the allelic effect-size distribution in NAFLD, it is likely that the majority of modifier loci will each individually have only a small effect, although a minority may have greater effect. 28 This seems consistent with evidence from genome-wide association studies (GWASs) in other conditions showing that disease-associated allelic variation is frequently noncoding and perturbs gene expression or exon splicing; subtle changes that in general have modest functional consequences compared with the much less common nonsynonymous coding sequence alterations. 28, 30 Supporting this, the majority of published association studies report allele relative risk ratios of 1.1 to 1.5. [30] [31] [32] As no single gene is sufficient to determine outcome, clear patterns of inheritance are not seen within kinships and so family-based gene linkage studies lack the necessary power to detect genetic variants as each individually confers only a modest effect. 15, 16 
Hypothesis-Driven Candidate-Gene Association Studies
The principal approach to the study of complex disease traits such as NAFLD has been the case-control disease-association study. These genetic association studies assess correlations between genetic variants and trait differences on a population scale and so have greater power to detect effect. 33 However, selection of candidate genes is founded on an assumed biologically plausible pathogenic role for the encoded protein. As these studies are reliant on there being a valid a priori hypotheses for gene selection, candidates are drawn from the limited pool of genes where biological function is already understood and considered relevant to the disease. 33, 34 These studies are therefore unlikely to identify a role for genes that were not already implicated. As will be discussed below, candidate-gene studies have only identified a small number of genes that are robustly and reproducibly associated with NAFLD.
Hypothesis Generation by Genome-Wide Association Studies
Patterns of association among single nucleotide polymorphisms (SNPs) throughout the genome may be characterized in terms of both linkage disequilibrium (LD; correlation between nearby variants on the same chromosome such that alleles are nonrandomly associated) and haplotype (a combination of alleles at multiple linked loci on a chromosome that are transmitted together). 35 The use of tag SNPs to serve as proxies for other SNPs that are in strong LD, allowed development of genotyping arrays that simultaneously test > 1 million different polymorphisms. These arrays permit the profiling of the majority of common (minor allele frequency [MAF] > 5%) variability in the human genome. [35] [36] [37] Genome-wide association studies have led to the identification of novel genes contributing to several important diseases. 34, 35 However, due to the nonhypothesis-driven nature of GWAS, the loci identified are frequently novel and would not otherwise have been linked to NAFLD. A corollary of this is that neither biological function nor pathogenic mechanisms are necessarily apparent and so additional study, both to confirm causality and elucidate the pathogenic mechanisms, is required. It is also apparent that a substantial proportion of disease heritability remains elusive and so GWASs are not a panacea. 32 The failure to achieve universal success in the study of complex diseases is in part because of the complexity of the phenotypes studied and difficulty in establishing sufficiently large, well-characterized patient cohorts. The latter is especially relevant to NAFLD where histologically characterized patients are required to assess modifiers of steatohepatitis and fibrosis. Current arrays do not yet capture rare variants with more modest effect size (MAF < 0.5%), nor are they effective at assessing disease associations with structural polymorphisms such as copy number variants, insertions, deletions, and inversions. 32, 35 
GWASs by Phenotype and Chronology
At the time of writing, several genome-scale studies for NAFLD have been reported (summarized in ►Table 1). 26, [38] [39] [40] [41] [42] [43] [44] These can be divided into three groups based on disease phenotype studied: (1) radiologically measured steatosis (HTGC), (2) histologically characterized NAFLD, and (3) clinical biochemistry phenotypes.
Radiologically Determined Steatosis-Based GWASs
The first GWAS in NAFLD, published in 2008, 26 was of relatively modest size by current standards. It examined 9,229 nonsynonymous SNPs in a North American population of diverse ethnicity (Hispanic, African American, and European ancestry) from the Dallas Heart Study. 26, 45 Hepatic triacylglycerol (TAG) accumulation was measured using noninvasive proton magnetic resonance spectroscopy ( 1 H-MRS). This study identified a single highly significant association between increased HTGC and the patatin-like phospholipase domain-containing 3 (PNPLA3) gene. 26 The index single nucleotide polymorphism (SNP) in PNPLA3 (rs738409 c.444 C > G, p.I148M) is a nonsynonymous cytosine to guanine nucleotide transversion mutation that results in an isoleucine to methionine amino acid change at codon 148. A gene dosage effect for I148M carriage was observed with a stepwise increase in HTGC with increasing carriage of the minor allele and homozygotes I148M carriage being associated with a twofold increase in HTGC. As alluded to earlier, minor-allele frequency correlated with ethnic differences in susceptibility to greater HTGC. 148M was most common in Hispanics (MAF 0.49), lower in those of European ancestry (0.23) and lowest in African Americans (0.17). Although less well characterized, this study also identified a second nonsynonymous SNP in PNPLA3 (rs6006460, p.S453I) that was associated with reduced HTGC and had the opposite ethnic distribution. 26, 46 The two SNPs in combination accounted for 72% of the ethnic variation in HTGC in the population studied.
In their later study, Speliotes et al employed a two-stage approach. 39 The initial exploratory meta-analysis of data from four cohorts (Age/Gene/Environment Susceptibility-Reykjavik Study, Old Order Amish Study, Family Heart Study, and Framingham Heart Study) using 2.4 million SNPs imputed to HapMap in 7,176 individuals of European ancestry remains the largest GWAS meta-analysis for NAFLD to date. 39 Adopting a permissive significance threshold (p < 10 À3 ), SNPs associated with HTGC were identified and then taken forward in a separate cohort of 592 patients with histologically characterized NAFLD as a candidate gene study. Variants located in or near PNPLA3 (rs738408), protein phosphatase 1, glucokinase regulator (GCKR; rs780094), regulatory (inhibitor) subunit 3B (PPP1R3B; rs4240624), and lysophospholipase-like 1 (LYPLAL1; rs12137855) were identified. In addition, a variant in the NCAN gene (rs2228603 c.274 C > T, p.Pro92Ser) in a region of chromosome 19 (19p13.11 ) was also associated with increased HTGC. 39 PNPLA3, GCKR, LYPLAL1, and NCAN (the 19p13.11 region), but not PPP1R3B were validated for histological steatosis, and additionally associated with lobular inflammation and/or fibrosis. In addition, variants in or near NCAN, GCKR, and PPP1R3B were associated with altered serum lipid levels and variants near GCKR and PPP1R3B affected glycemic traits. The rs738408 SNP in PNPLA3 identified in this study is in strong LD with rs738409, previously described by Romeo et al. 26 Although further study of each highlighted gene is still warranted to explore the associated pathogenic mechanisms, most were biologically plausible. GCKR encodes a regulator of carbohydrate metabolism and so is also highly relevant to NAFLD pathogenesis despite the precise causative variants within the gene remaining ill defined. LYPLAL1 encodes a protein involved in triglyceride breakdown and so is likely to be relevant. A variant in PPP1R3B (rs2126259), which encodes the catalytic subunit of protein phosphatase-1 and so may influence hepatic glycogen synthesis, has since been validated for HTGC in another GWAS. 42 These contrast with the 19p13.11 locus where attention had focused on the NCAN gene that contained the rs2228603 SNP. Although the association was subsequently validated in a separate cohort, 47 NCAN lacked biologically plausible evidence of a functional role in NAFLD while nearby genes had previously been associated with variations in plasma triglyceride and lowdensity lipoprotein levels and so were more likely candidates. 48, 49 Careful inspection of the LD patterns around rs2228603 and the 19p13.11 region suggested that the variant was in strong LD with a cluster of other SNPs up to 400 kb distant and so tagged > 20 other genes (►Fig. 1). This led us to question whether NCAN was indeed the causative gene. 14 Clarification on this point was provided by a subsequent GWAS based on a genome-wide exome chip in 2,736 individuals drawn from the same North American population as the original Romeo study. 43 In addition to again validating the association between PNPLA3 and NAFLD, Kozlitina et al determined that a nonsynonymous genetic variant within a gene of unknown function called TM6SF2, transmembrane 6 superfamily member 2 (rs58542926 c.449 C > T, p.Glu167Lys) at the 19p13.11 locus was associated with 1 H-MRS quantified HTGC. 43 Homozygote TM6SF2 rs58542926 minor (T) allele carriage was shown to be associated with a modest, but statistically significant increase in 1 H-MRS measured HTGC from 5.86 AE 0.25% in CC homozygotes to 15.04 AE 2.23% in TT homozygotes. 43 This TM6SF2 variant is in strong linkage disequilibrium with other SNPs around the 19p13.11 locus, including the rs2228603 SNP previously identified by Speliotes et al. 39 Crucially, conditional analyses demonstrated that TM6SF2 rs58542926, not NCAN rs2228603 was the causal variant driving the association with HTGC at this locus. 43, 50 Histologically Characterized NAFLD-Based GWASs Reflecting the difficulty establishing large patient cohorts that are characterized using invasive tests such as liver biopsy, most histologically based GWASs published to date have used relatively small cohorts. Four histologically based GWASs have been published to date. It is notable that these have not been as productive in terms of robustly identifying new genetic modifiers as the radiologically based studies. Chalasani et al reported the first histologically based GWAS in 236 female NAFLD patients. 38 This study did not report associations with individual components of the histological NAFLD activity score 51 such as steatosis; ballooning degeneration or portal inflammation Higher overall NAFLD activity scores were associated with a variant in the farnesyl diphosphate farnesyl transferase 1 (FDFT1, rs2645424), an enzyme with a role in cholesterol biosynthesis in a multivariate analysis adjusting for age, diabetes, HbA1c level, body mass index [BMI], and waist:hip ratio. Additional loci were associated with fibrosis (rs343062) and lobular inflammation (including rs1227756 in the COL13A1 gene). PNPLA3 was not associated with any aspect of the NAFLD phenotype in this study and the FDFT1 association was not replicated in a subsequent study using a cohort of 340 NAFLD. 52 Although the associations detected in this study are potentially interesting, they require further independent validation in larger patient cohorts.
Two Japanese histologically based studies have been published. 41, 53 The first, by Kawaguchi et al, 41 examined 484,751 SNPs in a cohort of 529 patients with biopsy-proven NAFLD characterized according to the Matteoni classification 54 and 932 population controls. The second study by Kitamoto et al 53 initially examined 261,540 SNPs in a cohort of 392 NAFLD patients and 934 population controls and then validated their findings in a cohort of 172 patients and 1,012 controls. Both studies confirmed the association between NAFLD and SNPs flanking the PNPLA3 gene in this ethnically distinct population, but identified no novel signals. Another study in 2,300 obese individuals again provided strong evidence of an association with PNPLA3 and identified a locus neighboring TM6SF2, both linked to a steatosis phenotype. 44 
Clinical Chemistry-Based GWASs
It is accepted that liver biochemistry correlates poorly with the presence of NAFLD or disease severity 55, 56 so that biochemical screening consistently reports a lower disease prevalence (3-12%) than imaging or histology-based studies. 57 Accepting these limitations, two GWASs have identified genes that influence plasma levels of alanine transaminase (ALT). 58, 59 The first of these studies found that PNPLA3 I148M was associated with raised serum ALT levels in populations of European and Indian-Asian descent. 58 A region spanning three genes on chromosome 10, APN1-ERLIN1-CHUK (rs11597390, rs11591741, rs11597086) that was also highlighted in this study 58 has since been associated with radiological steatosis and ALT levels in a GWAS-correlated meta-analysis, which flagged variants in ERLIN1-CHUK-CWF19L1. 42 The second of the two studies identified 42 loci at genome-wide significance levels (p < 1 Â 10 À8 ) in a cohort of 61,089 individuals. 59 Four loci were associated with elevations in ALT: rs6834314 near HSD17B13 and MAPK10; rs2954021 near TRIB1 (a gene that has previously been associated with variations in plasma cholesterol and triglyceride levels 48, 60, 61 ); rs10883437 near CPN1; and PNPLA3 rs738409. 59 The Chromosome 22 Locus: PNPLA3 Across all GWASs it is noteworthy that only two genes (PNPLA3 and TM6SF2) have been identified as potential modifiers in more than one study (►Fig. 2). Following its association with steatosis in the first reported NAFLD GWAS, there has remained considerable interest in the role of the PNPLA3 gene on chromosome 22 as a modifier of NAFLD pathogenesis. This association has now been independently replicated in numerous candidate-gene studies examining both adult [62] [63] [64] [65] [66] and pediatric [66] [67] [68] [69] NAFLD cohorts across differing ethnicities, as has the association with raised ALT/ aspartate aminotransferase (AST) levels. 70 There is also evidence from histologically based studies that the rs738409 (I148M) variant is associated with severity of steatohepatitis and greater fibrosis. 62, 64, 66 It has also been associated with greater response to dietary or lifestyle modification and so may be a marker of both greater risk and also greater benefit from intervention. 71, 72 The rise in the burden of NAFLD coincides with a marked increase in the incidence of HCC in many countries, [73] [74] [75] [76] and so it is timely to also consider whether genetic modifiers such as PNPLA3 may also increase the risk of NAFLD-associated HCC. The I148M variant has been associated with increased HCC risk in a mixed-etiology cohort, 77 the morbidly obese, 78 alcohol-related liver disease, [79] [80] [81] [82] and more variably, in chronic viral hepatitis. 79, 80, [82] [83] [84] This association is supported by a meta-analysis 85 86 In this study, comparison of genotype frequencies between the NAFLD-HCC cohort and an unselected United Kingdom (UK) general population sample (the MRC/Wellcome Trust UK 1958 Birth Cohort) identified a 12-fold increased risk of HCC (OR ¼ 12.19, 95% CI ¼ 6.89-21.58, p < 0.0001) for rs738409 minor (G) allele homozygotes relative to C-allele homozygotes. 86 These findings have led some to suggest that PNPLA3-associated HCC approaches monogenic inheritance. 87 We would caution against a move toward considering "PNPLA3-associated NAFLD," or by extension "PNPLA3-associated HCC," as distinct, monogenic conditions, but based on a reanalysis of the data from Liu et al 86 to assess sensitivity/specificity agree that there may be value in the PNPLA3 genotyping to select out those individuals least likely to develop HCC and therefore least likely to benefit from surveillance given the very high negative predictive value. 88 Further studies to determine the utility and health-economic merits of a multifactorial risk stratification that incorporates PNPLA3 rs738409 genotype along with other recognized risk factors for HCC are warranted.
The Challenge of Determining the Mechanistic Effects of PNPLA3 Variants
The PNPLA3 gene encodes a 481 amino acid protein that is structurally related to the principal TG hydrolase in adipose tissue, adipose triglyceride lipase (ATGL/PNPLA2). 46, 89 PNPLA3 differs from classical lipases in possessing a catalytic dyad (S47/D166) rather than the more usual triad. 90 Although the site of the I148M variant does not lie within this highly conserved catalytic site, the I148M amino acid substitution affects the hydrophobic substrate-binding groove and so may prevent substrate access to the catalytic site. 91 It is accepted that the modifier effect of PNPLA3 on the degree of hepatic steatosis is not due to a direct change in insulin sensitivity when assessed either by hyperinsulinemic, euglycemic clamp 63, 65 or plasma insulin response to oral glucose tolerance testing. 92 Furthermore, it does not alter the overall severity of the metabolic syndrome or confer a greater BMI, degree of dyslipidemia or prevalence of overt T2DM. 93 Current evidence suggests that the effects are more subtle, and that carriage of the PNPLA3 variation sensitizes the liver to metabolic stress due to nutritional calorific excess and adiposity, which is consistent with the concept of NASH as a complex disease trait. Thus, carriage of the I148M variant is associated with a greater degree of steatosis for any given degree of insulin resistance or adiposity. This concept is supported by the fact that I148M carriage is more strongly associated with raised AST/ALT in the presence of obesity. 92 Despite the strong genetic evidence, the physiological role of PNPLA3 and how this is perturbed by carriage of the I148M polymorphism is still incompletely understood. The structural changes affecting the catalytic site described above are consistent with the results of studies examining recombinant adiponutrin expressed in HUH-7 cells and the in vitro biochemical actions of purified PNPLA3. 91, 94 These demonstrate that PNPLA3 hydrolyses acylyglycerols with maximal hydrolytic activity observed against the three major glycerolipids, triacylglycerol (TG), diacylglycerol, and monoacylglycerol, with a strong preference for oleic acid as the acyl moiety; and that the I148M polymorphism is associated with substantially reduced enzymatic activity without reducing substrate affinity. 91, 94 Stable isotope tracer studies in 55 overweight/obese men and in vitro studies using rat McA-RH7777 cells that secrete ApoB-containing very-low-density lipoprotein-(VLDL-) like particles demonstrate that carriage of the I148M variant reduces VLDL secretion, an effect that may be indicative of a failure to mobilize TG from intracellular lipid droplets due to loss of TG hydrolase activity. 95 However, this is contentious as other groups have proposed that Genetics of NAFLD: Spotlight on PNPLA3 and TM6SF2 Anstee, Day 275 PNPLA3 may also possess lysophosphatidic acid acetyltransferase (LPAAT) activity that is enhanced by I148M, increasing TG synthesis. 96, 97 Interspecies differences in gene expression pattern have complicated in vivo mechanistic studies. PNPLA3 is expressed primarily in liver and adipose tissue, where it partitions to membranes and lipid droplets. 91 However, hepatic expression is highest in man, 98, 99 whereas adipose tissue expression is highest in mice. 100, 101 Moreover, the two species only share approximately 68% PNPLA3 homology. Hepatic PNPLA3 expression is increased after feeding, reduced by fasting, 46, 101 and is also raised in obesity. 63, 101 Insulin controls postprandial PNPLA3 expression through LXR/RXR and the transcription factor SREBP-1c. 98 Significantly, additional posttranslational control influenced by the constituents of the fatty acid milieu has also been described. 98 The presence of specific saturated (palmitate, C16:0), monounsaturated (oleate, C18:1) and polyunsaturated fatty acids (linoleic acid, C18:2) increased adiponutrin expression although very long chain fatty acids (e.g., arachidonic acid, C20:4 and eicosapentaenoic acid, C20:5) were not found to effect expression. 98 Reconciling the apparently conflicting findings of the in vivo experiments with the in vitro studies has proved challenging (►Table 2). Although the initial in vitro data was most consistent with a loss-of-function effect of the I148M polymorphism, deletion of Pnpla3 did not provoke hepatic TG accumulation, even when mice were fed a high-sucrose diet. 102, 103 Adenoviral mediated overexpression of wildtype human PNPLA3 was also unable to provoke steatosis; however, overexpression of the PNPLA3 I148M variant did cause steatosis. 91 More recently, studies have shown that neither hepatic nor adipose tissue overexpression of wildtype PNPLA3 promotes hepatic TG accumulation. Hepatic overexpression of the I148M variant form did, however, cause TG accumulation. 104 Importantly, three distinct metabolic effects were observed: increased synthesis of fatty acids and TG, impaired TG hydrolysis, and relative depletion of TG long chain polyunsaturated fatty acids. 104 Taken together, these data support the view that PNPLA3 acts to remodel TG in lipid droplets as they accumulate in the fed-state and that I148M affects multiple facets of this process. Furthermore, the apparent mixed enzymatic actions, coupled with the transcriptional regulation of PNPLA3 by feeding and the specific fatty acid profile suggests that the action of PNPLA3 may vary somewhat according to tissue and metabolic milieu. It is noteworthy that in this study hepatic overexpression of the I148M variant led to increased hepatic TG, but no associated changes in TNFα, α-smooth muscle actin or collagen type 1α mRNA expression were seen, providing no evidence that either inflammatory or fibrotic processes were active. 104 In an attempt to address the concerns that overexpression of human PNPLA3 I148M in mice may not have physiological fidelity, a recent study by Smagris et al used homologous recombination to introduce the Pnpla3 I148M variant (or a complete loss of function mutation that distorted the catalytic dyad, S47A) in mice while preserving normal physiological regulation of gene expression. 105 Consistent with the concept that the I148M variant sensitizes the liver to metabolic stress due to nutritional calorific excess and adiposity, a two to threefold increase in hepatic TG accumulation was seen when mice were fed high sucrose diet (but not standard chow), although these effects were not associated with an increase in ALT or circulating lipid levels. 105 Interestingly, Pnpla3 I148M was not associated with any changes in hepatic Srebp-1c expression or the expression profiles of its target genes, and once again no changes in TNFα, α-smooth muscle actin, or collagen type 1α mRNA expression were observed. A novel finding in this study was that hepatic TG accumulation in the knockin mice was accompanied by a 40-fold increase in either catalytically inactive PNPLA3 variant (I148M or S47A) on the surface of hepatic lipid droplets. This study is of significance as it reconciles the apparent disparity between the in vitro data suggesting a predominant loss-of-function effect of I148M 91, 94, 95 and the in vivo data where Pnpla3 knockout mice did not develop a NAFLD phenotype. 102, 103 The I148M variant confers a dominant-negative effect and so for the variant to drive NAFLD pathogenesis the presence of catalytically inactive PNPLA3 protein is necessary, not simply a complete absence of PNPLA3 activity. 105 While representing a substantial advance in our understanding of disease pathogenesis, the work by Li et al 104 and Smagris et al 105 underline the fact that further research is required to clarify how PNPLA3 drives not-only hepatic lipid accumulation, but also NAFLD progression to steatohepatitis, fibrosis, and hepatocellular carcinoma, where no clear mechanisms have been identified as yet. Addressing this point, only one study has offered any evidence of mechanistic link between PNPLA3 activity and hepatic fibrosis. 106 In that study, Pirazzi et al demonstrated that PNPLA3 is highly expressed in human hepatic stellate cells (HSCs) that purified wild-type PNPLA3 hydrolyzes retinyl palmitate into retinol and palmitic acid and that this enzymatic activity is markedly reduced by the I148M variant. 106 These findings suggest a potential link between HSCs, retinoid metabolism, and PNPLA3 in determining the susceptibility to hepatic fibrosis although no evidence that the observed effects altered HSC activation was provided and so further study is needed before this mechanism can be established as relevant.
The Chromosome 19 Locus: TM6SF2
The controversy regarding the causative gene within the 19p13.11 locus that was initially ascribed to NCAN has now largely been resolved. Kozlitina et al demonstrated that a nonsynonymous genetic variant within TM6SF2 (rs58542926 c.449 C > T, p.Glu167Lys) was associated with 1 H-MRS quantified HTGC. 43 This SNP lies within 50 kb of the NCAN gene variant (rs2228603) that had previously been associated with HTGC. 39, 47 Although both SNPs are in strong linkage disequilibrium (D' ¼ 0.926, r 2 ¼ 0.798), conditioning on the TM6SF2 variant abrogated the effect of the NCAN variant while the reverse did not occur, establishing that TM6SF2 rs58542926 is more strongly associated with the HTGC phenotype. 43 In vitro and in vivo functional studies have provided further support for this conclusion, but did not provide evidence demonstrating whether the effect of TM6SF2 was limited to hepatic steatosis or 111 meaning that the effect of the NAFLD promoting TM6SF2 allele will be more apparent in individuals of European ancestry than Hispanic or African ancestry. Inadequate statistical power to detect an effect on histological markers of disease progression coupled with a cohort exhibiting predominantly mild disease were contributory flaws in the small South American study. 109 This study contained only 226 NAFLD cases with histologically characterized disease of which 96 had simple steatosis and the remaining 130 exhibited only minimally active disease with little fibrosis (mean fibrosis stage of 1.4 out of 4). Conclusions drawn from this low quality study are questionable and are likely to represent type 2 error. Thus, the modifier role exerted by TM6SF2 rs58542926 (E167K) at the 19p13.11 locus has been robustly demonstrated across several large independent cohorts for NAFLD phenotypes ranging from steatosis to advanced fibrosis/cirrhosis. 39, 43, 50, 107, 110, 112 The Mechanistic Effects of TM6SF2 Variants
Little is known of the precise protein structure or functional role of the TM6SF2 gene product beyond that it is a multipass membrane protein. 113 Based on the analysis of coexpressed gene profiles in the Mouse Genome Informatics (MGI) database, TM6SF2 is predicted to function as a lipid transporter and may interact with proteins involved in intestinal absorption. 114 The TM6SF2 rs58542926 (E167K) missense mutation maps to an exposed nontransmembrane domain. Its effects appear to extend beyond liver disease alone. Using confocal microscopy, investigators observed localization of GFPtagged TM6SF2 to the endoplasmic reticulum and ER-Golgi intermediate compartments (ERGIC) in two human hepatoma cell lines. 112 In a series of elegant in vitro experiments they also found that knockdown of TM6SF2 reduced secretion of triglyceride-rich lipoproteins and APOB. This led to increased cellular triglyceride accumulation, which at the subcellular level, manifested as a marked increase in lipid droplet number and average size. Conversely, overexpression of TM6SF2 caused a decrease in the number and average size of lipid droplets. 112 A GWAS seeking modifiers of serum lipid levels and cardiovascular disease risk published around the same time as the studies linking TM6SF2 E167K with NAFLD supports these findings. 115 Holmen et al provided evidence that carriage of the more common TM6SF2 rs58542926 major allele was associated with dyslipidemia (raised serum LDL cholesterol and triglyceride) and increased myocardial infarction/cardiovascular disease risk while minor allele carriage was protective. 115 This finding was also consistent with several earlier reports regarding the 19p13.11 locus that had variously implicated the nearby genes NCAN, PBX4, and GMIP with dyslipidemia, associations that may probably now be ascribed to TM6SF2. 39, 48, 49 The association of TM6SF2 with dyslipidemia and atherosclerosis risk in humans was validated by another study examining two separate groups (a NAFLD patient cohort and an obese population cohort). Patients with NAFLD that carried the E167K variant encoding the minor allele were found to have a lower risk of developing carotid plaques (OR ¼ 0.49, 95% CI ¼ 0.25-0.94) while E167K carriers among a group of 1,819 obese individuals had significantly lower serum lipid levels and a lower incidence of cardiovascular events (hazard ratio ¼ 0.61; 95% CI ¼ 0.39-0.95). 107 As demonstrated in a study examining 300 Finnish subjects, the effects of TM6SF2 on HTGC and circulating lipid profiles are mediated without inducing greater hepatic insulin resistance. 116 Indeed, the effects of insulin on glucose production and lipolysis were significantly higher in carriers of the TM6SF2 E167K variant than in wild-type subjects. 116 The most recent GWAS, addressing the impact of low-frequency and rare variants on lipid levels, examined 9.6 million genetic variants achieved through 1,000 Genomes Project imputation in 62,166 samples. 114 Here, two variants within TM6SF2 were identified that together explained the entire 19p13.11 regional association with lipid levels (TC, LDL-C, and TG). These variants were rs58542926 (E167K) and a second, less common, missense mutation located in the fifth transmembrane domain (rs1874290064, L156P). 114 Further support for the parallel effects of TM6SF2 on NAFLD pathogenesis and hepatic lipid handling is provided by a series of in vivo studies observing the effects of altered gene expression in mice. Overexpression of human wild-type TM6SF2 in liver resulted in higher total cholesterol (TC), lowdensity lipoprotein (LDL) cholesterol, triglycerides (TGs), and lower high-density lipoprotein (HDL) cholesterol, whereas knockdown of mouse Tm6sf2 in liver resulted in decreased serum TC. 115 Knock down of mouse Tm6sf2 in vivo also resulted in increased hepatic lipid accumulation and a reduction in serum TG, LDL, and VLDL secretion. 43 Taken together, these in vivo 43, 115 and in vitro 43, 112, 115 functional studies suggest that TM6SF2 controls hepatic lipid efflux, with its deletion or mutation resulting in a reduction in lipoprotein secretion (VLDL, TG, and APOB) coincident with increased hepatocellular lipid droplet size and TG accumulation. Because the E167K variant results in lower TC in humans and expression levels of the E167K protein is lower than the wildtype form, these data further indicate that the E167K variant confers a loss of function to the protein that may be both qualitative and quantitative. 43, 115 TM6SF2 and Cardiovascular Disease: The "Catch-22" Paradigm Based on available evidence, we recently described the "TM6SF2 Catch-22" paradigm. 117 Here, on a background of insulin resistance and metabolic stress, TM6SF2 acts as a determinant of metabolic syndrome-related end-organ damage and thus clinical outcome: protecting the liver at the This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 133, 134 In 702 biopsy-proven NAFLD cases, carriage of nonsynonymous SNPs in ENPP1 (rs1044498, encoding Lys121Gln) and IRS1 (rs1801278, encoding Gln972Arg) reduced AKT activation, promoted insulin resistance, and were independently associated with greater fibrosis. 135 
GCKR Glucokinase regulatory protein
GCKR SNP rs780094 is in strong LD with a functional nonsynonymous SNP (rs1260326, encoding Pro446Leu) and has been associated with hepatic TG accumulation in several studies. 39, 59 It is also associated with greater NAFLD fibrosis. 136
SLC2A1
Solute carrier family 2, facilitated glucose transporter member 1
A study examining 3,072 SNPs across 92 candidate genes identified variants in SLC2A1 associated with NAFLD, independent of insulin resistance or T2DM. 137 Downregulation of SLC2A1 in vitro promoted lipid accumulation and increased oxidative stress, potentially linking the key pathogenic features of NAFLD: oxidative injury and increased lipid storage.
TCF7L2
Transcription factor 7-like 2 A role for TCF7L2, which has a key role in Wnt signaling and has been implicated in T2DM, has been reported in NAFLD. 138 PPARG Peroxisome proliferator-activated receptor γ A loss-of-function SNP (rs1805192, encoding Pro12Ala) impairs transcriptional activation and affects insulin sensitivity. 139 Carriage of haplotypes including the Pro12Ala allele was associated with progressive NAFLD, 140 but two studies found no association. 141, 142 Steatosis Hepatic lipid import or synthesis SLC27A5 Very long chain acyl-CoA synthetase Two principal isoforms of FATPs are expressed in the liver, SLC27A2 (also known as FATP2) and SLC27A5 (also known as FATP5). 143 Silencing Slc27a5 reverses diet-induced NAFLD and improves hyperglycemia in mice. 144 Carriage of the SLC27A5 rs56225452 promoter region polymorphism has been associated with higher ALT levels, and greater postprandial insulin and triglyceride levels. 144 In patients with histologically proven NAFLD, the effect of BMI 
Gene
Protein Study details and comments coactivator to regulate fatty acid metabolism. 146, 147 Variants have been associated with multiple components of the metabolic syndrome. 146, 148 Although a large case-control study found no association with T2DM, obesity, or related traits in 17,538 individuals, 149 a meta-analysis in 8, 504 individuals found that the LPIN1 rs13412852 [T] allele was associated with lower BMI and insulin levels. 150 This same polymorphism was underrepresented in pediatric (but not adult) NAFLD with a suggestion of less severe liver damage. 151 Hepatic lipid export or oxidation in steatosis PNPLA3 Patatin-like phospholipase domain-containing 3
The nonsynonymous 617C > G nucleotide transversion mutation SNP (rs738409, encoding Ile148Met) has been consistently associated with steatosis, steatohepatitis, and hepatic fibrosis; however, function remains incompletely understood, 26, 62 TM6SF2 Transmembrane 6 super family 2
The TM6SF2 rs58542926 minor allele is associated with greater steatosis, steatohepatitis, and NAFLD fibrosis. The major allele is associated with dyslipidemia and greater CVD risk. 43, 50, 107, 115 NR1I2 Nuclear receptor subfamily 1 group I member 2 (also known as pregnane X receptor)
NR1I2 encodes a transcription factor that regulates hepatic detoxification 152 and acts through CD36 (fatty-acid translocase) and various lipogenic enzymes to control lipid metabolism 153 Nr1i2-deficient mice develop steatosis. 153 Two SNPs (rs7643645 and rs2461823) were associated with NAFLD and were also a predictor of disease severity. 154 PPARα Peroxisome proliferator-activated receptor α PPAR-α is a molecular sensor for long chain fatty acids, eicosanoids, and fibrates 155 ; activated by increased hepatocyte fatty-acid load, it limits TAG accumulation by increasing fatty acid oxidation Carriage of a nonsynonymous SNP (rs1800234, encoding Val227Ala) increases activity, and was associated with NAFLD despite reduced BMI. 156 Genetics of NAFLD: Spotlight on PNPLA3 and TM6SF2 Anstee, Day 281
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Genetics of NAFLD: Spotlight on PNPLA3 and TM6SF2 Anstee, Day 283 expense of increased risk of atherosclerosis and cardiovascular disease or vice versa (►Fig. 3). 117 It is widely accepted that NAFLD is associated with cardiovascular disease, indeed the majority of patients with NAFLD will ultimately die a cardiovascular rather than a liver-related death. 3,10,57 However, these conditions can be dissociated: Individuals carrying the minor (T) allele of TM6SF2 rs58542926 (167K) appear prone to developing NAFLD with advanced fibrosis and so are more likely to experience liver-related rather than cardiovascular morbidity and mortality. 43, 50, 107 Conversely, carriage of the Callele is associated with dyslipidemia and cardiovascular disease. 107, 115 As yet, it remains unclear if the effects of TM6SF2 variants are sufficient to eclipse the many environmental and other genetic factors that determine disease outcome at an individual level, and so merit inclusion of genotype testing within a stratified medicine approach. Nevertheless, further study of this and other NAFLD-associated human genetic variants will greatly inform our understanding of the pathophysiology and interrelationship between NAFLD and its associated metabolic traits.
Other Genetic Modifiers in NAFLD
The current understanding of disease pathogenesis has been achieved through both clinical research and the translational study of specific animal models. 12 It is generally accepted that the initiating events in NAFLD are dependent on the development of obesity and insulin resistance. 3 Together, these produce an increased free fatty acid (FFA) flux within the liver which in turn places hepatocytes under considerable metabolic load and promotes hepatocyte lipotoxicity, increased oxidative stress secondary to free radicals produced during βand ω-FFA oxidation, and endoplasmic reticulum stress. Hepatocellular TAG accumulation (steatosis) is a histologically apparent epiphenomenon reflecting these metabolic changes and is best considered an early adaptive response through which potentially lipotoxic FFAs are partitioned into relatively stable intracellular TAG stores. 118 Ultimately, these insults combine with the additive effects of endotoxin/TLR4 induced Kupffer cell cytokine release and immune mediated hepatocellular injury to induce cellular damage and activate cell death pathways, marking the transition to steatohepatitis. [119] [120] [121] If these processes persist stellate cell activation, collagen deposition and hepatic fibrosis occur. 122 Potential genetic modifiers therefore fall into four broad categories: (1) those that influence glucose metabolism and insulin sensitivity; (2) those that perturb the handling of fatty acids and the accumulation of TAG in the liver; (3) those that determine progression to NASH (for example, modifiers of oxidative stress, endotoxin response or cytokine and adipokine activity); and (4) those that might influence hepatic fibrogenesis. 13 Drawing on the results of the GWAS discussed earlier and the numerous candidate gene studies that have been reported, ►Table 3 summarizes the genes that have been associated with aspects of the NAFLD phenotype according to this schema. These are discussed in depth in our previous reviews of the field. 13, 14 It should be remembered, however, that only a minority of the genes that have been associated with NAFLD either in GWAS or through candidate-gene analysis have been independently validated and can be considered of proven importance. Indeed, if only those genes that have been robustly validated in large independent studies or through the use of transmission disequilibrium testing 123 are considered, the list only includes patatinlike phospholipase domain-containing 3 (PNPLA3), 26,62-66 transmembrane 6 superfamily member 2 (TM6SF2), 43, 50, 107 mitochondrial superoxide dismutase 2 (SOD2), 124, 125 phosphatidylethanolamine N-methyltransferase (PEMT), 126,127 fatty acid desaturase 1 (FADS1) 128 and Kruppel-like factor-6 (KLF6). 129, 130 Conclusions Nonalcoholic fatty liver disease is a complex disease in which subtle interpatient genetic variations and environmental factors interact to determine disease phenotype and progression. The relative importance of these factors will vary between populations depending on background modifier genes, lifestyle choices/challenges, and other factors such as the intestinal microbiome. Beyond identifying associations, it is important to understand the mechanisms through which these variations exert effects and to translate these findings into clinical utility where possible. 
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